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Background
T cell immunotherapy with genetically modified T cells
expressing chimeric antigen receptors (CARs) has
shown promise in preclinical models as well as early
clinical studies. However, patients with solid tumors
often do not respond as well as patients with hematologi-
cal malignancies. This lack of efficacy for solid tumors is
most likely due to several factors including a) emergence
of immune escape mutants, and b) inability of tumor-
specific T cells to recognize and destroy the vascular bed
of solid tumors, which is critical for their malignant
growth. The aim of this project is to generate CARs speci-
fic for tumor endothelial marker (TEM) 8, and evaluate
their anti-vasculature and anti-tumor activity in preclinical
tumor models.
Methods/results
We generated a retroviral encoding a TEM8-specific CAR
consisting of the TEM8-specific single chain variable frag-
ment AF344, a hinge/transmembrane domain, and a
CD28.41BB.z endodomain. CD3/CD28-activated T cells
were transduced with RD114-pseudotyped retroviral parti-
cles to generate TEM8-specific T cells and CAR expres-
sion was confirmed by FACS analysis. To evaluate the
functionality of TEM8-specific T cells we used TEM8-
negative cell lines (U373, A549, LM7, 293T) and 293T
cells that were genetically modified to either express
human TEM8 (293T.hTEM8) or murine TEM8 (293T.
mTEM8). TEM8-specific T cells recognized target cells in
an antigen-dependent fashion as judged by their ability to
secrete pro-inflammatory cytokines (IFN-g and IL-2)
in coculture assays, and kill TEM8-positive target cells.
Importantly, TEM8-specific T cells readily recogni-
zed mTEM8-positive target cells, which will allow us to
evaluate the safety and efficacy of TEM8-specific T cells in
xenograft and immune competent murine tumor models.
Conclusion
We have constructed a TEM8-specific CAR and have
shown that T cells expressing this CAR recognize and kill
hTEM8- or mTEM8-positive target cells. Animal studies
are in progress to determine their safety and efficacy.
Targeting the tumor vasculature with TEM8-specific
T cells may improve current T cell immunotherapies for
solid tumors.
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